Startseite Circulating miR-21, miR-210 and miR-146a as potential biomarkers to differentiate acute tubular necrosis from hepatorenal syndrome in patients with liver cirrhosis: a pilot study
Artikel
Lizenziert
Nicht lizenziert Erfordert eine Authentifizierung

Circulating miR-21, miR-210 and miR-146a as potential biomarkers to differentiate acute tubular necrosis from hepatorenal syndrome in patients with liver cirrhosis: a pilot study

  • Mona Mohamed Watany ORCID logo EMAIL logo , Rasha Youssef Hagag und Hanaa Ibrahim Okda
Veröffentlicht/Copyright: 5. Januar 2018
Veröffentlichen auch Sie bei De Gruyter Brill
Manuskript einreichen Informationen für Autor*innen
Clinical Chemistry and Laboratory Medicine (CCLM)
Aus der Zeitschrift Clinical Chemistry and Laboratory Medicine (CCLM) Band 56 Heft 5

Abstract

Background:

Acute kidney injury (AKI) in cirrhotic patients may be functional (hepatorenal syndrome [HRS]) or structural (acute tubular necrosis [ATN]). The differentiation between these two conditions remains challenging; no definite biomarker with a clear cutoff value had been declared. miRNAs seem to be attractive innovative biomarkers to identify the nature of kidney injury in cirrhotic patients. This study aimed to investigate the possibility of using miR-21, miR-210 and miR-146a as differentiating markers between HRS and ATN.

Methods:

This pilot case control study included 50 patients with liver cirrhosis; 25 with HRS and another 25 with ATN beside 30 healthy controls. Real-time qPCR was used to measure the circulating miRNA tested.

Results:

Higher levels of miR-21 were observed in both ATN and HRS vs. controls with statistically significant difference between ATN and HRS. The means were 9.466±3.21 in ATN, 2.670±1.387 in HRS and 1.090±0.586 in controls. miR-146a and miR-210 were both significantly lower in ATN and HRS compared to controls with statistically significant differences between ATN and HRS. The means of miR-210 were 1.020±0.643, 1.640±0.605 and 3.0±0.532 in ATN, HRS and controls, respectively. The means of miR-146a were 2.543±1.929, 4.98±1.353 and 6.553±0.426 in ATN, HRS and controls, respectively. ROC analyses proved that the three studied mi-RNAs can be used as differentiating biomarkers between ATN and HRS with the best performance observed with mi-21 achieving specificity and sensitivity equal 96%.

Conclusions:

miR-21, miR-210 and miR-146a may be candidate differentiating markers between HRS and ATN in cirrhotic patients.

Keywords: acute tubular necrosis; hepatorenal syndrome; liver cirrhosis; miRNA
Corresponding author: Dr. Mona Mohamed Watany, MD, Clinical Pathology Department, Faculty of Medicine, Tanta University Hospital, El Geish Street, Tanta, Gharbia Governorate, Egypt, Phone: 00201224337432

  1. Author contributions: All the authors have accepted responsibility for the entire content of this submitted manuscript and approved submission.

  2. Research funding: None declared.

  3. Employment or leadership: None declared.

  4. Honorarium: None declared.

  5. Competing interests: The funding organization(s) played no role in the study design; in the collection, analysis, and interpretation of data; in the writing of the report; or in the decision to submit the report for publication.

References

1. World Health Organization. 2015. Available from: http://www.who.int/countries/egy/en/. Accessed: 29 June 2017.Suche in Google Scholar

2. Francoz C, Nadim MK, Durand F. Kidney biomarkers in cirrhosis. J Hepatol 2016;65:809–24.10.1016/j.jhep.2016.05.025Suche in Google Scholar PubMed

3. Durand F, Valla D. Assessment of the prognosis of cirrhosis: child-pugh versus MELD. J Hepatol 2005;42(Suppl 1):S100–7.10.1016/j.jhep.2004.11.015Suche in Google Scholar PubMed

4. Angeli P, Gines P, Wong F, Bernardi M, Boyer TD, Gerbes A, et al. Diagnosis and management of acute kidney injury in patients with cirrhosis: revised consensus recommendations of the International Club of Ascites (vol. 62, pg. 968, 2015). J Hepatol. 2015;63:290.10.1016/j.jhep.2015.04.001Suche in Google Scholar

5. Al-Ismaili Z, Palijan A, Zappitelli M. Biomarkers of acute kidney injury in children: discovery, evaluation, and clinical application. Pediatr Nephrol 2011;26:29–40.10.1007/s00467-010-1576-0Suche in Google Scholar PubMed

6. Levey AS, Stevens LA, Schmid CH, Zhang YP, Castro AF, Feldman HI, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med 2009;150:604–12.10.7326/0003-4819-150-9-200905050-00006Suche in Google Scholar PubMed PubMed Central

7. Francoz C, Prie D, AbdelRazek W, Moreau R, Mandot A, Belghiti J, et al. Inaccuracies of creatinine and creatinine-based equations in candidates for liver transplantation with low creatinine: impact on the model for end-stage liver disease score. Liver Transpl 2010;16:1169–77.10.1002/lt.22128Suche in Google Scholar PubMed

8. Martensson J, Martling CR, Bell M. Novel biomarkers of acute kidney injury and failure: clinical applicability. Br J Anaesth 2012;109:843–50.10.1093/bja/aes357Suche in Google Scholar PubMed

9. Krol J, Loedige I, Filipowicz W. The widespread regulation of microRNA biogenesis, function and decay. Nat Rev Genet 2010;11:597–610.10.1038/nrg2843Suche in Google Scholar PubMed

10. miRBase. 2017. Available from: http://www.mirbase.org/cgi-bin/browse.pl?org=hsa. Accessed: 29 June 2017.Suche in Google Scholar

11. Trionfini P, Benigni A, Remuzzi G. MicroRNAs in kidney physiology and disease. Nat Rev Nephrol 2015;11:23–33.10.1038/nrneph.2014.202Suche in Google Scholar PubMed

12. Wei QQ, Mi QS, Dong Z. The regulation and function of micrornas in kidney diseases. IUBMB Life 2013;65:602–14.10.1002/iub.1174Suche in Google Scholar PubMed PubMed Central

13. Fleischhacker M, Schmidt B. Circulating nucleic acids (CNAs) and cancer – a survey. Biochim Biophys Acta 2007;1775: 181–232.10.1016/j.bbcan.2006.10.001Suche in Google Scholar PubMed

14. Chen X, Ba Y, Ma L, Cai X, Yin Y, Wang K, et al. Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res 2008;18:997–1006.10.1038/cr.2008.282Suche in Google Scholar PubMed

15. Aguado-Fraile E, Ramos E, Conde E, Rodriguez M, Liano F, Garcia-Bermejo ML. microRNAs in the kidney: Novel biomarkers of Acute Kidney Injury. Nefrologia 2013;33:826–34.Suche in Google Scholar

16. Fan PC, Chen CC, Chen YC, Chang YS, Chu PH. MicroRNAs in acute kidney injury. Hum Genomics 2016;10:29.10.1186/s40246-016-0085-zSuche in Google Scholar PubMed PubMed Central

17. Lorenzen JM, Kielstein JT, Hafer C, Gupta SK, Kumpers P, Faulhaber-Walter R, et al. Circulating miR-210 predicts survival in critically Ill patients with acute kidney injury. Clin J Am Soc Nephro 2011;6:1540–6.10.2215/CJN.00430111Suche in Google Scholar PubMed

18. Cantaluppi V, Gatti S, Medica D, Figliolini F, Bruno S, Deregibus MC, et al. Microvesicles derived from endothelial progenitor cells protect the kidney from ischemia-reperfusion injury by microRNA-dependent reprogramming of resident renal cells. Kidney Int 2012;82:412–27.10.1038/ki.2012.105Suche in Google Scholar PubMed

19. Aguado-Fraile E, Ramos E, Conde E, Rodriguez M, Martin-Gomez L, Lietor A, et al. A pilot study identifying a set of microRNAs as precise diagnostic biomarkers of acute kidney injury. PLoS One 2015;10:e0127175.10.1371/journal.pone.0127175Suche in Google Scholar PubMed PubMed Central

20. Godwin JG, Ge XP, Stephan K, Jurisch A, Tullius SG, Iacomini J. Identification of a microRNA signature of renal ischemia reperfusion injury. P Natl Acad Sci USA 2010;107:14339–44.10.1073/pnas.0912701107Suche in Google Scholar PubMed PubMed Central

21. Jia P, Teng J, Zou JZ, Fang Y, Wu X, Liang MY, et al. Xenon protects against septic acute kidney injury via miR-21 target signaling pathway. Crit Care Med 2015;43:E250–9.10.1097/CCM.0000000000001001Suche in Google Scholar PubMed PubMed Central

22. Xu XL, Kriegel AJ, Liu Y, Usa K, Mladinov D, Liu H, et al. Delayed ischemic preconditioning contributes to renal protection by upregulation of miR-21. Kidney Int 2012;82:1167–75.10.1038/ki.2012.241Suche in Google Scholar PubMed PubMed Central

23. Hu HL, Jiang W, Xi XQ, Zou C, Ye ZF. MicroRNA-21 attenuates renal ischemia reperfusion injury via targeting caspase signaling in mice. Am J Nephrol 2014;40:215–23.10.1159/000368202Suche in Google Scholar PubMed

24. Chau BN, Xin CY, Hartner J, Ren SY, Castano AP, Linn G, et al. MicroRNA-21 promotes fibrosis of the kidney by silencing metabolic pathways. Sci Transl Med 2012;4:121ra18.10.1126/scitranslmed.3003205Suche in Google Scholar PubMed PubMed Central

25. Zarjou A, Yang SZ, Abraham E, Agarwal A, Liu G. Identification of a microRNA signature in renal fibrosis: role of miR-21. Am J Physiol-Renal 2011;301:F793–801.10.1152/ajprenal.00273.2011Suche in Google Scholar PubMed PubMed Central

26. Denby L, Ramdas V, Lu RF, Conway BR, Grant JS, Dickinson B, et al. MicroRNA-214 antagonism protects against renal fibrosis. J Am Soc Nephrol 2014;25:65–80.10.1681/ASN.2013010072Suche in Google Scholar PubMed PubMed Central

27. Du J, Cao XQ, Zou L, Chen Y, Guo J, Chen ZJ, et al. MicroRNA-21 and risk of severe acute kidney injury and poor outcomes after adult cardiac surgery. PLoS One 2013;8:e63390.10.1371/journal.pone.0063390Suche in Google Scholar PubMed PubMed Central

28. Hartleb M, Gutkowski K. Kidneys in chronic liver diseases. World J Gastroenterol 2012;18:3035–49.10.3748/wjg.v18.i24.3035Suche in Google Scholar PubMed PubMed Central

29. Weiss JB, Eisenhardt SU, Stark GB, Bode C, Moser M, Grundmann S. MicroRNAs in ischemia-reperfusion injury. Am J Cardiovasc Dis 2012;2:237–47.Suche in Google Scholar

30. Godwin JG, Ge X, Stephan K, Jurisch A, Tullius SG, Iacomini J. Identification of a microRNA signature of renal ischemia reperfusion injury. Proc Natl Acad Sci USA 2010;107:14339–44.10.1073/pnas.0912701107Suche in Google Scholar PubMed PubMed Central

31. Banaei S. Novel role of microRNAs in renal ischemia reperfusion injury. Ren Fail 2015;37:1073–9.10.3109/0886022X.2015.1055697Suche in Google Scholar PubMed

32. Lorenzen JM. Vascular and circulating microRNAs in renal ischaemia–reperfusion injury. J Physiol 2015;593(Pt 8):1777–84.10.1113/JP270318Suche in Google Scholar PubMed PubMed Central

33. Park KM, Kramers C, Vayssier-Taussat M, Chen A, Bonventre JV. Prevention of kidney ischemia/reperfusion-induced functional injury, MAPK and MAPK kinase activation, and inflammation by remote transient ureteral obstruction. J Biol Chem 2002;277:2040–9.10.1074/jbc.M107525200Suche in Google Scholar PubMed

34. Frankel LB, Christoffersen NR, Jacobsen A, Lindow M, Krogh A, Lund AH. Programmed cell death 4 (PDCD4) is an important functional target of the microRNA miR-21 in breast cancer cells. J Biol Chem 2008;283:1026–33.10.1074/jbc.M707224200Suche in Google Scholar PubMed

35. Kaucsar T, Revesz C, Godo M, Krenacs T, Albert M, Szalay CI, et al. Activation of the miR-17 Family and miR-21 During Murine Kidney Ischemia-Reperfusion Injury. Nucleic Acid Ther 2013;23:344–54.10.1089/nat.2013.0438Suche in Google Scholar PubMed PubMed Central

36. Denby L, Ramdas V, McBride MW, Wang J, Robinson H, McClure J, et al. miR-21 and miR-214 Are Consistently Modulated during Renal Injury in Rodent Models. Am J Pathol 2011;179:661–72.10.1016/j.ajpath.2011.04.021Suche in Google Scholar PubMed PubMed Central

37. Saikumar J, Hoffmann D, Kim T-M, Gonzalez VR, Zhang Q, Goering PL, et al. Expression, circulation, and excretion profile of MicroRNA-21, -155, and -18a following acute kidney injury. Toxicol Sci 2012;129:256–67.10.1093/toxsci/kfs210Suche in Google Scholar PubMed PubMed Central

38. Liu F, Lou YL, Wu J, Ruan QF, Xie A, Guo F, et al. Upregulation of MicroRNA-210 regulates renal angiogenesis mediated by activation of VEGF signaling pathway under ischemia/perfusion injury in vivo and in vitro. Kidney Blood Press Res 2012;35:182–91.10.1159/000331054Suche in Google Scholar PubMed

39. Cui R, Xu J, Chen X, Zhu WL. Global miRNA expression is temporally correlated with acute kidney injury in mice. Peerj 2016;4:e1729.10.7717/peerj.1729Suche in Google Scholar PubMed PubMed Central

40. Meyrier A, Hill GS, Simon P. Ischemic renal diseases: new insights into old entities. Kidney Int 1998;54:2–13.10.1046/j.1523-1755.1998.00968.xSuche in Google Scholar PubMed

41. Francoz C, Glotz D, Moreau R, Durand F. The evaluation of renal function and disease in patients with cirrhosis. J Hepatol 2010;52:605–13.10.1016/j.jhep.2009.11.025Suche in Google Scholar PubMed

Supplemental Material:

The online version of this article offers supplementary material (https://doi.org/10.1515/cclm-2017-0483).

Received: 2017-5-29
Accepted: 2017-11-23
Published Online: 2018-1-5
Published in Print: 2018-4-25

©2018 Walter de Gruyter GmbH, Berlin/Boston

Artikel in diesem Heft

  1. Frontmatter
  2. Editorials
  3. Scientific publishing in the “predatory” era
  4. The influence of age and other biological variables on the estimation of reference limits of cardiac troponin T
  5. Reviews
  6. Prognostic and predictive value of EGFR and EGFR-ligands in blood of breast cancer patients: a systematic review
  7. GSTP1 methylation in cancer: a liquid biopsy biomarker?
  8. Opinion Paper
  9. Practical recommendations for managing hemolyzed samples in clinical chemistry testing
  10. Genetics and Molecular Diagnostics
  11. Non-invasive prenatal diagnosis of paternally inherited disorders from maternal plasma: detection of NF1 and CFTR mutations using droplet digital PCR
  12. Circulating miR-21, miR-210 and miR-146a as potential biomarkers to differentiate acute tubular necrosis from hepatorenal syndrome in patients with liver cirrhosis: a pilot study
  13. Pleiotropy of ABO gene: correlation of rs644234 with E-selectin and lipid levels
  14. General Clinical Chemistry and Laboratory Medicine
  15. Three-year customer satisfaction survey in laboratory medicine in a Chinese university hospital
  16. Measurement of sirolimus concentrations in human blood using an automated electrochemiluminescence immunoassay (ECLIA): a multicenter evaluation
  17. Precision, accuracy, cross reactivity and comparability of serum indices measurement on Abbott Architect c8000, Beckman Coulter AU5800 and Roche Cobas 6000 c501 clinical chemistry analyzers
  18. Commutability of control materials for external quality assessment of serum apolipoprotein A-I measurement
  19. Development of a new biochip array for APOE4 classification from plasma samples using immunoassay-based methods
  20. Validation of a high-performance liquid chromatography method for thiopurine S-methyltransferase activity in whole blood using 6-mercaptopurine as substrate
  21. Increased serum concentrations of soluble ST2 are associated with pulmonary complications and mortality in polytraumatized patients
  22. Reference Values and Biological Variations
  23. Determination of age- and sex-specific 99th percentiles for high-sensitive troponin T from patients: an analytical imprecision- and partitioning-based approach
  24. Effect of preanalytical and analytical variables on the clinical utility of mean platelet volume
  25. Serum prolactin levels across pregnancy and the establishment of reference intervals
  26. Gender-partitioned patient medians of serum albumin requested by general practitioners for the assessment of analytical stability
  27. Cancer Diagnostics
  28. Detection of EGFR, KRAS and BRAF mutations in metastatic cells from cerebrospinal fluid
  29. Cardiovascular Diseases
  30. No additional value of conventional and high-sensitivity cardiac troponin over clinical scoring systems in the differential diagnosis of type 1 vs. type 2 myocardial infarction
  31. Letters to the Editor
  32. Rare inclusion bodies within monocytes at accelerated phase of Chediak-Higashi syndrome
  33. A specific abnormal scattergram of peripheral blood leukocytes that may suggest hairy cell leukemia
  34. Spuriously low lymphocyte count associated with pseudoerythroblastemia in a patient with chronic lymphocytic leukemia treated with ibrutinib
  35. Performance evaluation of a new automated fourth-generation HIV Ag/Ab combination chemiluminescence immunoassay
  36. False increase of glycated hemoglobin due to aspirin interference in Tosoh G8 analyzer
  37. Assessment of in vitro stability: a call for harmonization across studies
  38. Comparison between blood gas analyzer and central laboratory analyzer for the determination of electrolytes in patients with acute respiratory acidosis
https://doi.org/10.1515/cclm-2017-0483
Schlagwörter für diesen Artikel
acute tubular necrosis; hepatorenal syndrome; liver cirrhosis; miRNA

Artikel in diesem Heft

  1. Frontmatter
  2. Editorials
  3. Scientific publishing in the “predatory” era
  4. The influence of age and other biological variables on the estimation of reference limits of cardiac troponin T
  5. Reviews
  6. Prognostic and predictive value of EGFR and EGFR-ligands in blood of breast cancer patients: a systematic review
  7. GSTP1 methylation in cancer: a liquid biopsy biomarker?
  8. Opinion Paper
  9. Practical recommendations for managing hemolyzed samples in clinical chemistry testing
  10. Genetics and Molecular Diagnostics
  11. Non-invasive prenatal diagnosis of paternally inherited disorders from maternal plasma: detection of NF1 and CFTR mutations using droplet digital PCR
  12. Circulating miR-21, miR-210 and miR-146a as potential biomarkers to differentiate acute tubular necrosis from hepatorenal syndrome in patients with liver cirrhosis: a pilot study
  13. Pleiotropy of ABO gene: correlation of rs644234 with E-selectin and lipid levels
  14. General Clinical Chemistry and Laboratory Medicine
  15. Three-year customer satisfaction survey in laboratory medicine in a Chinese university hospital
  16. Measurement of sirolimus concentrations in human blood using an automated electrochemiluminescence immunoassay (ECLIA): a multicenter evaluation
  17. Precision, accuracy, cross reactivity and comparability of serum indices measurement on Abbott Architect c8000, Beckman Coulter AU5800 and Roche Cobas 6000 c501 clinical chemistry analyzers
  18. Commutability of control materials for external quality assessment of serum apolipoprotein A-I measurement
  19. Development of a new biochip array for APOE4 classification from plasma samples using immunoassay-based methods
  20. Validation of a high-performance liquid chromatography method for thiopurine S-methyltransferase activity in whole blood using 6-mercaptopurine as substrate
  21. Increased serum concentrations of soluble ST2 are associated with pulmonary complications and mortality in polytraumatized patients
  22. Reference Values and Biological Variations
  23. Determination of age- and sex-specific 99th percentiles for high-sensitive troponin T from patients: an analytical imprecision- and partitioning-based approach
  24. Effect of preanalytical and analytical variables on the clinical utility of mean platelet volume
  25. Serum prolactin levels across pregnancy and the establishment of reference intervals
  26. Gender-partitioned patient medians of serum albumin requested by general practitioners for the assessment of analytical stability
  27. Cancer Diagnostics
  28. Detection of EGFR, KRAS and BRAF mutations in metastatic cells from cerebrospinal fluid
  29. Cardiovascular Diseases
  30. No additional value of conventional and high-sensitivity cardiac troponin over clinical scoring systems in the differential diagnosis of type 1 vs. type 2 myocardial infarction
  31. Letters to the Editor
  32. Rare inclusion bodies within monocytes at accelerated phase of Chediak-Higashi syndrome
  33. A specific abnormal scattergram of peripheral blood leukocytes that may suggest hairy cell leukemia
  34. Spuriously low lymphocyte count associated with pseudoerythroblastemia in a patient with chronic lymphocytic leukemia treated with ibrutinib
  35. Performance evaluation of a new automated fourth-generation HIV Ag/Ab combination chemiluminescence immunoassay
  36. False increase of glycated hemoglobin due to aspirin interference in Tosoh G8 analyzer
  37. Assessment of in vitro stability: a call for harmonization across studies
  38. Comparison between blood gas analyzer and central laboratory analyzer for the determination of electrolytes in patients with acute respiratory acidosis
Jetzt anmelden und 20% sparen
Institutioneller Zugang
Wie funktioniert Authentifizierung?
Haben Sie eine Idee, wie wir unsere Website verbessern können?
Bitte schreiben Sie uns.
© 2025 De Gruyter Brill
Heruntergeladen am 26.9.2025 von https://www.degruyterbrill.com/document/doi/10.1515/cclm-2017-0483/html
Button zum nach oben scrollen